Privia Health Group (PRVA) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for May 21, 2025, to be held virtually; registration required by May 20, 2025.
Proxy materials, including the notice, proxy statement, and annual report, are available online; paper copies can be requested.
Voting matters and shareholder proposals
Election of three Class III director nominees to serve until the 2028 annual meeting: Pamela Kimmet, Patricia Maryland, and Shawn Morris.
Advisory vote to approve compensation of named executive officers.
Ratification of PricewaterhouseCoopers LLP as independent auditor for the fiscal year ending December 31, 2025.
Board recommends voting FOR all nominees and proposals.
Board of directors and corporate governance
Three director nominees are up for election to the Board, each to serve a three-year term until 2028.
Latest events from Privia Health Group
- 2025 saw double-digit growth in all key metrics, with 2026 guidance projecting further expansion.PRVA
Q4 202526 Feb 2026 - Q2 2024 delivered strong growth, raised guidance, and maintained a robust cash position.PRVA
Q2 20242 Feb 2026 - Tech-enabled platform drives profitable growth and high retention in value-based care.PRVA
The 44th Annual William Blair Growth Stock Conference1 Feb 2026 - Raised 2024 guidance after strong Q3 growth, Indiana entry, and robust cash position.PRVA
Q3 202416 Jan 2026 - Record provider adds, robust cash flow, and expanding value-based care support 20%+ EBITDA growth.PRVA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026 - 2024 outperformed guidance; 2025 targets further growth amid value-based care challenges.PRVA
Q4 202416 Dec 2025 - Board maintains flexible governance, emphasizing ongoing evaluation and stockholder input.PRVA
Proxy Filing1 Dec 2025 - Board recommends director elections, say-on-pay, and auditor ratification, with strong governance and ESG focus.PRVA
Proxy Filing1 Dec 2025 - Raised 2025 guidance after robust Q2 growth in revenue, EBITDA, and provider network.PRVA
Q2 202523 Nov 2025